I have always maintained that the more progress that adult stem cell researchers make, the harder it will be for mainstream media outlets to maintain their news blockade that has prevented important success stories from reaching the public consciousness. This New York Times report, hopefully, is a harbinger of better journalism to come. Skin stem cells have been transformed into blood vessel tissue and used to treat patients. From the story:
From a snippet of a patient’s skin, researchers have grown blood vessels in a laboratory and then implanted them to restore blood flow around the patient’s damaged arteries and veins...Eventually, these tissues would then be used in the needed treatments. According to the Times’ story, this procedure could be used to save the fingers and toes of diabetes patients or treat congenital heart defects in children, as just two examples.
The skin biopsy takes about 15 minutes. Under local anesthesia, a doctor removes a piece of skin, including a strip of vein about an inch long, from the back of the hand or inner wrist. Then technicians use enzymes to extract fibroblast cells from the skin and endothelial cells from the inner lining of the vein. The cells are grown by the millions as sheets in a laboratory. The fibroblasts provide a mechanical backbone for the sheets that are peeled and rolled into a tube.
We are on the verge of tremendous medical progress—and most of it is entirely ethical. Bravo!
Time is short, so I’ll be direct: FIRST THINGS needs you. And we need you by December 31 at 11:59 p.m., when the clock will strike zero. Give now at supportfirstthings.com.
First Things does not hesitate to call out what is bad. Today, there is much to call out. Yet our editors, authors, and readers like you share a greater purpose. And we are guided by a deeper, more enduring hope.
Your gift of $50, $100, or even $250 or more will bring this message of hope to many more people in the new year.
Make your gift now at supportfirstthings.com..
First Things needs you. I’m confident you’ll answer the call.